Changes in learning and memory functions, Aβ deposition, APP protein levels, BACE1, p-tau and related inflammatory mediators are critical indicators of the pathology and severity of AD and contribute to evaluating the therapeutic effect. This evidence concerns the gene MAPT and Alzheimer disease.